Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 30 September 2024, 14:00 HKT/SGT
Share:
    

Source: Olympus
Olympus Launches VISERA S, a New Imaging Platform
Supporting patient comfort, improved diagnostics, and streamlined workflow, available in Europe, parts of Asia and Oceania

TOKYO, Sept 30, 2024 - (JCN Newswire) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced the launch of VISERA S1, the all-in-one imaging platform with stroboscopy. The new video platform integrates advanced diagnostic capabilities, including NBI (Narrow Band Imaging) technology2, and forms part of the expanding Ear, Nose and Throat (ENT) solution from Olympus. The company will first launch VISERA S from September 2024 in Europe and parts of Asia and Oceania. VISERA S will later be introduced in other regions after product registration has been approved by the local regulatory bodies.

Designed to help improve ENT diagnostic efficiency and patient experience, VISERA S offers an integrated video diagnosis system that brings NBI to a range of patient settings, from outpatient offices to private practices. With VISERA S, the clinician can switch between white light, NBI and stroboscopy capabilities and use the sharp HD quality visualization to detect, characterize and treat ENT disease.

VISERA S VIDEO SYSTEM CENTER OLYMPUS OTV-S500
VISERA S VIDEO SYSTEM CENTER OLYMPUS OTV-S500
  • An all-in-one platform with NBI and advanced visualization

VISERA S, with its improved color resolution, depth of field and minimized noise, is expected to improve the contrast and visibility of vascular structures and mucosa.

  • Integrated model with video system center and multiple light sources

In previous models, the video system and strobe light source were separated, but VISERA S integrates them into a single unit. This allows switching between white light mode, NBI and stroboscopy modes at the touch of a button, which is expected to improve operability.

  • Expanded compatibility

Enhancing Olympus’ commitment to continuous diagnostic and patient-centered innovation, VISERA S supports a HD camera head, which provides higher image quality than the legacy video platform. VISERA S is also highly adaptable by being compatible with other Olympus scopes, camera heads, monitors and other existing video equipment.

  • Streamline and simplify patient care

VISERA S is engineered to reduce effort and improve patient experience without complexity. While previous models could only store still images, the new imaging platform can store higher-quality still images and record video, capturing a comprehensive procedural record and contributing to comprehensive reporting.

Comment from Martijn Koster, Global ENT Business Unit Leader at Olympus

“VISERA S brings the power of early, patient-friendly diagnosis to the office, outpatient and private practice ENT care settings. By listening and innovating around the needs of our customers and their patients, we envision that the variety of diagnostic tools on the VISERA S can potentially diagnose disease earlier in the patient care pathway. The VISERA S will help ENT physicians deliver next-generation diagnostic imaging that advances their efforts to save lives through earlier diagnosis.”

1 This product is also applicable to urology and obstetrics and gynecology.
2 NBI (Narrow band imaging) is an imaging technique for examining features such as the small blood vessels in mucosa and the surface patterns. NBI highlights tissue by illuminating it with two narrow bands (wavelengths) of light that are absorbed by the hemoglobin in blood without making use of a fluorescence dye.

About Olympus

At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_Corp.

Media contact:
Mail: Global-Public_Relations@olympus.com 

Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com  




Topic: Press release summary
Source: Olympus

Sectors: Healthcare & Pharm, MedTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Olympus
Sept 20, 2024 14:00 HKT/SGT
Olympus Launches New 4K Camera Head for Urological Endoscopy
June 12, 2024 10:00 HKT/SGT
Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, India
Mar 27, 2024 14:00 HKT/SGT
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System
Jan 24, 2024 14:00 HKT/SGT
Olympus Closes the Acquisition of Korean Gastrointestinal Stent Company, Taewoong Medical Co., Ltd
Dec 11, 2023 10:00 HKT/SGT
Olympus Named to Dow Jones Sustainability World Index for Three Consecutive Years
Dec 7, 2023 10:00 HKT/SGT
Vesica AI Selected as Winner of Inaugural Olympus Asia Pacific Innovation Program
Nov 30, 2023 10:00 HKT/SGT
Olympus's Net-Zero Targets Approved by SBTi
Oct 6, 2023 20:00 HKT/SGT
Olympus Names Dr. John de Csepel as Chief Medical Officer
July 20, 2023 10:00 HKT/SGT
Olympus to Launch Development Support Project in Kenya for the Diagnosis of Gastrointestinal Diseases
July 20, 2023 10:00 HKT/SGT
Olympus to Launch Development Support Project in Kenya for the Diagnosis of Gastrointestinal Diseases
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: